country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-149963

Copy Link Print Information

PROTAC CDK9 degrader-6

1 Cited Publications

Based on 1 Customer Validation

PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 sepcifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC₅₀s of 0.10 μM and 0.14 μM for the CDK9₄₂ and CDK9₅₅ isoforms, respectively.

For research use only. We do not sell to patients.

CAS No.: 2935587-91-8
Formula: C₄₂H₄₉Cl₂N₉O₈
Molecular Weight:878.80

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

PROTAC CDK9 degrader-6 Chemical Structure

CAS No.: 2935587-91-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Purity & Documentation
References
Calculators
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

CDK9₄₂

0.03 μM (DC₅₀)

CDK9₅₅

0.05 μM (DC₅₀)

All PROTACs Isoforms :

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MOLM-13	IC₅₀	42.08 μM Compound: 16	Anticancer activity against human MOLM-13 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Anticancer activity against human MOLM-13 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 37071962]
MV4-11	EC₅₀	0.2 μM Compound: 16	Anticancer activity against human MV4-11 cells assessed as cell growth inhibition for 6 hrs followed by compound washout measured after 24 hrs by Annexin V/Propidium iodide staining based flow cytometric analysis Anticancer activity against human MV4-11 cells assessed as cell growth inhibition for 6 hrs followed by compound washout measured after 24 hrs by Annexin V/Propidium iodide staining based flow cytometric analysis	[PMID: 37071962]

In Vitro

PROTAC CDK9 degrader-6 (compound 16) (1 μM; 6 h) decreases the protein level of MCL2, and competely degrades CDK9 in MV411 cells^[1].
PROTAC CDK9 degrader-6 (1 μM; 1-6 h) time-dependently decreases the protein level of MCL2, and CDK9, and remaines suppression for 24 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MV411 cells
Concentration:

1 μM
Incubation Time:

1 h, 2 h, 4 h, 6 h
Result:

Degraded CDK9 starting at 2 h incubation and reaching a plateau at 4 h.
Remained suppressed for 24 h with some recurrence at 48 h after finished treatment.

Chemical Information

CAS No. 2935587-91-8
Molecular Weight 878.80
Formula C₄₂H₄₉Cl₂N₉O₈
SMILES

O=C(NCCCCCCCCCCC(N1CCC(CC1)NC(C2=NNC=C2NC(C3=C(C=CC=C3Cl)Cl)=O)=O)=O)CNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

J Med Chem

Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer. [Abstract]

2025 Feb 13;68(3):2528-2550. PMID: 39895086

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (269 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Tokarski RJ 2nd, et al. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. Eur J Med Chem. 2023 Jun 5;254:115342. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

PROTAC CDK9 degrader-6

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

100 mg

Get Quote In-stock

Price: USD 0.00

Biological Activity
- Description
- IC50 & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PROTAC CDK9 degrader-6

Publications Citing Use of MedChemExpress (MCE) PROTAC CDK9 degrader-6

All PROTACs Isoforms

All CDK Isoforms

Biological Activity

Chemical Information

Publications (1)

Purity & Documentation

References

Calculators

Help & FAQs

PROTAC CDK9 degrader-6 Related Classifications

Cat. No.: HY-149963